{"filing":{"accession_number":"0001193125-26-368288","cik":"0001620463","ticker":"LONA","company_name":"LeonaBio, Inc.","form":"8-K","filing_date":"2026-08-26","report_date":"2026-08-26","primary_document":"lona-20260826.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1620463/000119312526368288/lona-20260826.htm"},"events":[{"id":29726,"run_id":27233,"accession_number":"0001193125-26-368288","anchor_item_number":"8.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"summary":"The filing discloses the issuance of 23,031,494 Series A Common Warrants with an exercise price of $6.35 per share, which if exercised in full would provide approximately $146.2 million in capital. The warrants become exercisable upon the enrollment of the 500th subject in the ELAINE-3 Trial (triggered by this 8-K announcement), making this a material dilutive issuance. While the filing also announces a clinical trial milestone, the substantive disclosure centers on the warrant exercise mechanics and potential capital raise, characteristic of dilutive equity issuances.","company_name":"LeonaBio, Inc.","ticker":"LONA","filing_date":"2026-08-26","form":"8-K","submitted_at":null,"items":[{"id":32104,"accession_number":"0001193125-26-368288","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The filing discloses the issuance of 23,031,494 Series A Common Warrants with an exercise price of $6.35 per share, which if exercised in full would provide approximately $146.2 million in capital. The warrants become exercisable upon the enrollment of the 500th subject in the ELAINE-3 Trial (triggered by this 8-K announcement), making this a material dilutive issuance. While the filing also announces a clinical trial milestone, the substantive disclosure centers on the warrant exercise mechanics and potential capital raise, characteristic of dilutive equity issuances.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-26T20:07:14.851216+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":32104,"accession_number":"0001193125-26-368288","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The filing discloses the issuance of 23,031,494 Series A Common Warrants with an exercise price of $6.35 per share, which if exercised in full would provide approximately $146.2 million in capital. The warrants become exercisable upon the enrollment of the 500th subject in the ELAINE-3 Trial (triggered by this 8-K announcement), making this a material dilutive issuance. While the filing also announces a clinical trial milestone, the substantive disclosure centers on the warrant exercise mechanics and potential capital raise, characteristic of dilutive equity issuances.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-26T20:07:14.851216+00:00","company_name":"LeonaBio, Inc.","ticker":"LONA","filing_date":"2026-08-26"}]}